PG545 Prevents Osteoarthritis Development by Regulating PI3K/AKT/mTOR Signaling and Activating Chondrocyte Autophagy
Pharmacology · 2023 · 108 (6) · 576-588
DOI: 10.1159/000532078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology, online erschienen am 11.10.2023. Verfasst von Peiyu Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, First Affiliated Hospital of Kunming Medical University, Kunming, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Osteoarthritis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Osteoarthritis (OA) is a degenerative disease common in the elderly and is characterized by joint pain, swelling, and restricted movement. In recent years, heparanase has been reported to play an important role in the development of osteoarthritic cartilage. PG545 is a heparan sulfate mimetic with heparanase inhibitory activity. In this study, the therapeutic effects and possible mechanisms of PG545 were investigated in a chondrocyte injury model induced by interleukin-1β (IL -1β).
Methods
Following treatment with PG545 or the autophagy inhibitor 3-methyladenine (3-MA), chondrocyte viability was detected using Cell Counting Kit-8 and fluorescein diacetate/propidium iodide double staining. The apoptosis rate of chondrocytes was determined by flow cytometry. Expression of light chain 3 and P62 was monitored by immunofluorescence labeling. Western blot, lentivirus infection with red fluorescent protein and green fluorescent protein, and quantitative real-time polymerase chain reaction were used to determine the expression levels of chondrocyte markers, apoptosis-related factors, autophagy proteins, and key proteins of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway. The expression and activity of stress-specific enzymes such as malondialdehyde, superoxide dismutase, and catalase (CAT) were investigated. Chondrocytes with ATG5 knockdown were used to investigate the relationship between the therapeutic effect of PG545 and autophagy. The therapeutic effect of PG545 was verified in vivo.
Results
PG545 had a significant protective effect on chondrocytes by reducing oxidative stress, apoptosis, and degradation of chondrocytes and increasing chondrocyte proliferation. PG545 was effective in inducing autophagy in IL-1β-treated cells, while 3-MA attenuated the effect. The PI3K/Akt/mTOR pathway may be involved in the promotion of autophagy and OA treatment by PG545.
Conclusion
PG545 was able to restore impaired autophagy and autophagic flux via the PI3K/Akt/mTOR pathway, thereby delaying the progression of OA, suggesting that PG545 may be a novel therapeutic approach for OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, First Affiliated Hospital of Kunming Medical University, Kunming, China.
- Department of Sport Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, China.
- Department of Respiratory Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, China.
Zitieren
APA
Guo, P., Li, H., Wang, X., Li, X., & Li, X. (2023). PG545 Prevents Osteoarthritis Development by Regulating PI3K/AKT/mTOR Signaling and Activating Chondrocyte Autophagy. Pharmacology, 108(6), 576-588. https://doi.org/10.1159/000532078
Vancouver
Guo P, Li H, Wang X, Li X, Li X. PG545 Prevents Osteoarthritis Development by Regulating PI3K/AKT/mTOR Signaling and Activating Chondrocyte Autophagy. Pharmacology. 2023;108(6):576-588. doi:10.1159/000532078
BibTeX
@article{Guo2023,
author = {Guo, Peiyu and Li, Hua and Wang, Xuming and Li, Xingguo and Li, Xi},
title = {PG545 Prevents Osteoarthritis Development by Regulating PI3K/AKT/mTOR Signaling and Activating Chondrocyte Autophagy},
journal = {Pharmacology},
year = {2023},
volume = {108},
number = {6},
pages = {576--588},
doi = {10.1159/000532078}
}
EUVIMED